Q1 2025 Earnings Call Transcript May 13, 2025 GRAIL, Inc. beats earnings expectations. Reported EPS is $-3.09, expectations were $-4.03. Operator: Good day, ladies and gentlemen. And welcome to the ...

Cologuard is a colon cancer screening test you can do at home. It’s a noninvasive, stool-based test that comes in a kit. You use the kit to collect a stool sample. Then you send the sample to a lab ...

In future, more personalised, tailored screening for all cancers rather than ... Those scenarios are on the horizon, according to the head of the Cancer Research UK, Dr Catherine Elliott.

The findings underscore the necessity of evaluating the effectiveness of lung cancer screening in non-high-risk populations and developing biomarker-based enrichment strategies to refine pre ...

Calls for routine screening have intensified after Sir Chris Hoy, the Olympic cyclist, announced his terminal prostate cancer diagnosis last year. However, experts agree that current testing ...

Blood tests with enzyme profiling diagnose pancreatic cancer in Stage I and Stage II The method adds efficiency to cancer detection while delivering better performance than prevailing biomarkers ...

Springfield resident and prostate cancer survivor Tom Pamer was one of many to make his way to the Ohio Statehouse this week to advocate for legislation that he hopes will help save lives.

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could ...

The sample can then be analyzed using routine methods in clinical labs.” The current standard for prostate cancer screening relies heavily on a blood test that measures PSA levels. While elevated PSA ...

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access. In this clip, Raymond Osarogiagbon, MD ...

One such is being discussed with Professor Rakesh Heer of Imperial College London, co-author of the study and head of TRANSFORM, the UK’s national prostate cancer study, which offers a platform for ...